Efficacy of adjuvant capecitabine in residual triple negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study

Basit Öğe Kaydı
dc.authoridMutlu, Arda Ulas/0000-0001-7499-7155
dc.authoridCavdar, Eyyup/0000-0001-5885-3047
dc.authoridSahin, Elif/0000-0002-1976-3951
dc.contributor.authorTasci, Elif Senocak
dc.contributor.authorKutlu, Yasin
dc.contributor.authorOlmez, Omer Fatih
dc.contributor.authorMutlu, Arda Ulas
dc.contributor.authorGundogdu, Yasemin
dc.contributor.authorSeyyar, Mustafa
dc.contributor.authorSahin, Elif
dc.date.accessioned2024-09-29T16:02:53Z
dc.date.available2024-09-29T16:02:53Z
dc.date.issued2024
dc.departmentKarabük Üniversitesien_US
dc.description.abstractBackgroundTriple negative breast cancer (TNBC) is characterized by high rates of recurrence, especially in patients with residual disease after neoadjuvant chemotherapy (NAC). Capecitabine is being used as standard adjuvant treatment in residual TNBC. We aimed to investigate the real-life data regarding the efficacy of capecitabine in residual TNBC.Design and methodsIn this retrospective multicenter study, TNBC patients with residual disease were evaluated. Patients, who received standard anthracycline and taxane-based NAC and adjuvant capecitabine were eligible. Overall survival (OS), disease free survival (DFS) and toxicity were analyzed.Results170 TNBC patients with residual disease were included. Of these, 62.9% were premenopausal. At the time of analysis, the recurrence rate was 30% and death rate was 18%. The 3-year DFS and OS were 66% and 74%, respectively. In patients treated with adjuvant capecitabine, residual node positive disease stood out as an independent predictor of DFS (p = 0.024) and OS (p = 0.032). Undergoing mastectomy and the presence of T2 residual tumor was independent predictors of DFS (p = 0.016) and OS (p = 0.006), respectively.ConclusionThe efficacy of capecitabine was found lower compared to previous studies. Selected patients may have further benefit from addition of capecitabine. The toxicity associated with capecitabine was found lower than anticipated.en_US
dc.identifier.doi10.1080/14656566.2024.2337261
dc.identifier.endpage484en_US
dc.identifier.issn1465-6566
dc.identifier.issn1744-7666
dc.identifier.issue4en_US
dc.identifier.pmid38568074en_US
dc.identifier.scopus2-s2.0-85189873288en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage477en_US
dc.identifier.urihttps://doi.org/10.1080/14656566.2024.2337261
dc.identifier.urihttps://hdl.handle.net/20.500.14619/5767
dc.identifier.volume25en_US
dc.identifier.wosWOS:001196635300001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofExpert Opinion On Pharmacotherapyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCapecitabineen_US
dc.subjectbreast canceren_US
dc.subjectresidual tumoren_US
dc.subjecttriple negativeen_US
dc.subjecttoxicityen_US
dc.titleEfficacy of adjuvant capecitabine in residual triple negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu